peptide
Survodutide
emergingPhase 2/3 Clinical TrialsInjection
Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim. The glucagon component adds liver fat reduction, promising for fatty liver disease alongside obesity.
Key facts
- Classification
- Peptide — Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim.
- Primary benefits
- Fat Loss (9/10) · Gut Health (5/10) · Longevity (4/10)
- Administration
- Injection
- Doses studied
- Start at 0.6 mg per week and gradually increase. Up to 4.8 mg/week was tested for weight loss; 6.0 mg was tested in liver disease (MASH) trials. Meant for long-term use.
- Evidence strength
- Emerging — 20 peer-reviewed studies
- Stacks well with
- 5-Amino-1MQ, MOTS-c, BPC-157
- Legal status
- Phase 2/3 Clinical Trials · not prescribable in US · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 3 peptides
- Regulatory
- Phase 2/3 Clinical Trials
Goal coverage · Survodutide
🔥 Fat Loss9/10
🫃 Gut Health5/10
⏳ Longevity4/10
🧊 Inflammation4/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications